BNTC
Income statement / Annual
Last year (2025), Benitec Biopharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Benitec Biopharma Inc.'s net income was -$37.92 M.
See Benitec Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$75.00 K |
$73.00 K |
$59.00 K |
$97.00 K |
$11.32 M |
$455.45 K |
$450.31 K |
$346.51 K |
| Cost of Revenue |
$396.00 K
|
$343.00 K
|
$381.00 K
|
$9.00 K
|
$123.00 K
|
-$185.00 K
|
$426.51 K
|
$331.30 K
|
$209.02 K
|
$103.80 K
|
| Gross Profit |
-$396.00 K
|
-$343.00 K
|
-$306.00 K
|
$64.00 K
|
-$64.00 K
|
$282.00 K
|
$10.89 M
|
$124.15 K
|
$241.29 K
|
$242.70 K
|
| Gross Profit Ratio |
0
|
0
|
-4.08
|
0.88
|
-1.08
|
2.91
|
0.96
|
0.27
|
0.54
|
0.7
|
| Research and Development Expenses |
$18.33 M
|
$15.61 M
|
$12.77 M
|
$11.27 M
|
$7.02 M
|
$3.00 M
|
$2.17 M
|
$5.06 M
|
$5.32 M
|
$9.92 M
|
| General & Administrative Expenses |
$23.43 M
|
$0.00
|
$0.00
|
$6.65 M
|
$6.51 M
|
$5.57 M
|
$6.66 M
|
$6.41 M
|
$6.99 M
|
$8.96 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$23.43 M
|
$6.65 M
|
$6.00 M
|
$6.65 M
|
$6.51 M
|
$5.57 M
|
$6.66 M
|
$6.41 M
|
$6.99 M
|
$8.96 M
|
| Other Expenses |
-$396.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.00 K
|
$154.77 K
|
$734.59
|
-$7.91 M
|
-$2.68 M
|
| Operating Expenses |
$41.37 M
|
$22.26 M
|
$18.78 M
|
$17.92 M
|
$13.53 M
|
$8.56 M
|
$8.99 M
|
$8.68 M
|
$4.40 M
|
$16.20 M
|
| Cost And Expenses |
$41.77 M
|
$22.60 M
|
$19.16 M
|
$17.93 M
|
$13.66 M
|
$8.38 M
|
$9.41 M
|
$9.01 M
|
$4.61 M
|
$16.31 M
|
| Interest Income |
$3.29 M
|
$904.00 K
|
$0.00
|
$0.00
|
$0.00
|
$62.00 K
|
$122.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$33.00 K
|
$32.00 K
|
$6.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$69.33 K
|
$343.00 K
|
$381.00 K
|
$392.00 K
|
$424.00 K
|
$374.00 K
|
$154.77 K
|
$142.51 K
|
$166.75 K
|
$11.54 M
|
| EBITDA |
-$41.70 M |
-$21.41 M |
-$19.15 M |
-$17.85 M |
-$13.45 M |
-$7.91 M |
$2.74 M |
-$8.59 M |
-$4.19 M |
-$13.42 M |
| EBITDA Ratio |
0
|
0
|
-255.31
|
-244.58
|
-228
|
-81.52
|
0.24
|
-18.85
|
-9.31
|
-38.72
|
| Operating Income Ratio |
0
|
0
|
-254.41
|
-244.58
|
-230.44
|
-85.37
|
0.18
|
-18.78
|
-35.36
|
-72.04
|
| Total Other Income/Expenses Net |
$3.85 M
|
$847.00 K
|
-$481.00 K
|
-$354.00 K
|
-$286.00 K
|
$7.00 K
|
$606.03 K
|
$179.24 K
|
$11.55 M
|
$6.46 M
|
| Income Before Tax |
-$37.92 M
|
-$21.75 M
|
-$19.56 M
|
-$18.21 M
|
-$13.88 M
|
-$8.27 M
|
$2.87 M
|
-$8.55 M
|
-$4.37 M
|
-$18.50 M
|
| Income Before Tax Ratio |
0
|
0
|
-260.83
|
-249.42
|
-235.29
|
-85.3
|
0.25
|
-18.77
|
-9.71
|
-53.4
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$864.22 K
|
$1.47 K
|
$0.00
|
$0.00
|
| Net Income |
-$37.92 M
|
-$21.75 M
|
-$19.56 M
|
-$18.21 M
|
-$13.88 M
|
-$8.27 M
|
$2.87 M
|
-$8.55 M
|
-$4.37 M
|
-$18.50 M
|
| Net Income Ratio |
0
|
0
|
-260.83
|
-249.42
|
-235.29
|
-85.3
|
0.25
|
-18.77
|
-9.71
|
-53.4
|
| EPS |
-1.05 |
-2.68 |
-14.12 |
-19.31 |
-27.27 |
-69.09 |
28.445 |
-103.605 |
-63.555 |
-331.56 |
| EPS Diluted |
-1.05 |
-2.68 |
-14.12 |
-19.31 |
-27.27 |
-69.09 |
28.445 |
-103.605 |
-63.555 |
-331.56 |
| Weighted Average Shares Out |
$36.21 M
|
$10.26 M
|
$1.39 M
|
$1.92 M
|
$1.01 M
|
$240.28 K
|
$201.59 K
|
$165.06 K
|
$137.59 K
|
$111.62 K
|
| Weighted Average Shares Out Diluted |
$36.21 M
|
$10.28 M
|
$1.39 M
|
$1.92 M
|
$1.01 M
|
$240.28 K
|
$201.59 K
|
$165.06 K
|
$137.60 K
|
$111.62 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
